Phase II study of the association of Velcade [bortezomib] to R-CHOP [rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone] in the treatment of B cell lymphoma [non-Hodgkin's lymphoma].

Trial Profile

Phase II study of the association of Velcade [bortezomib] to R-CHOP [rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone] in the treatment of B cell lymphoma [non-Hodgkin's lymphoma].

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Oct 2009 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 01 Oct 2009 Results published in Cancer.
    • 24 Jul 2007 Status changed from "in progress" to "completed". The trial was closed in April 2006 after enrollment of 49 patients, and results data were reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top